NewAmsterdam Pharma (NAMS)

Executive Summary

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing novel oral therapies for cardiovascular disease, with a lead program targeting cholesteryl ester transfer protein (CETP) inhibition. The company aims to address the significant unmet need in patients with uncontrolled lipid levels despite existing treatments. Founded in 2019 and headquartered in Naarden, Netherlands, NewAmsterdam has advanced its lead candidate, obicetrapib, through Phase 3 trials for dyslipidemia and atherosclerotic cardiovascular disease. The recent completion of the BROADWAY trial has shown promising reductions in LDL-C and other atherogenic lipids with a favorable safety profile, positioning obicetrapib as a potential best-in-class therapy. With a strong focus on oral administration and once-daily dosing, the drug could offer a convenient option for patients not achieving goals on statins or ezetimibe. The company is also exploring obicetrapib in combination with other agents and in high-risk populations. Backed by a valuation of ~$3.6 billion and listed on NASDAQ (NAMS), NewAmsterdam is well-capitalized to pursue regulatory filings. Key upcoming catalysts include the Phase 3 TANDEM trial readout in combination with ezetimibe and the initiation of the Phase 3 PREVAIL outcomes trial, which could support expanded indications and potential approval in 2026-2027.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 TANDEM trial top-line results for obicetrapib in combination with ezetimibe85% success
• Q4 2026Initiation of Phase 3 PREVAIL cardiovascular outcomes trial90% success
• Q1 2027Potential FDA submission for obicetrapib in dyslipidemia80% success